ロリテトラサイクリン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

ロリテトラサイクリン 価格

ロリテトラサイクリン 化学特性,用途語,生産方法

• 効能

  抗生物質, タンパク質合成阻害薬

• 説明

  Rolitetracycline was synthesized in 1958. Bristol-Myers Laboratories prepared it from tetracycline by introducing a pyrrolidinylmethyl moiety. This antibiotic is very soluble in water and more stable than tetracycline under acidic conditions. Rolitetracycline is used by intravenous injection, and its nitrate is used by both intravenous and intramuscular injections for therapy of the same infections as those treated by tetracycline.

• 使用

  Rolitetracycline is a tetracycline antibiotic that may be given intravenously or intramuscularly in serious bacterial infections when oral administration is not practicable.

• 定義

  ChEBI: A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.

• 一般的な説明

  Rolitetracycline, N-(pyrrolidinomethyl)tetracycline(Syntetrin), was introduced for use by intramuscular or intravenousinjection. This derivative is made by condensingtetracycline with pyrrolidine and formaldehyde in the presenceof tert-butyl alcohol. It is very soluble in water (1 g dissolvesin about 1 mL) and provides a means of injecting theantibiotic in a small volume of solution. It has been recommendedfor cases when the oral dosage forms are not suitable,but it is no longer widely used.

• 応用例（製薬）

  2-N-pyrrolidinomethyl-tetracycline. A semisynthetic derivative of tetracycline supplied as the nitrate sesquihydrate for parenteral use.
  It is not absorbed from the gastrointestinal tract. It is highly soluble and therefore can be administered parenterally. Peak plasma concentrations of 4–6 mg/L occur at 0.5–1 h after 350 mg intravenously. The plasma elimination half-life is 5–8 h. About 50% of the dose is excreted in the urine, producing high concentrations.
  Intravenous administration is occasionally accompanied by abnormal taste, shivering and rigors, hot flushes, facial reddening, dizziness and, rarely, circulatory collapse. Symptoms of myasthenia gravis have occasionally been exacerbated.

ロリテトラサイクリン 生産企業

Global(48)Suppliers

751-97-3, ロリテトラサイクリン キーワード